LPX Lipoxen

    RNS Number : 3402F
  Lipoxen PLC
  08 October 2008
   

    Lipoxen PLC 
    ("Lipoxen" or "the Company") 
      
    Change of Broker and Nominated Adviser Name 

    Following its change of name from Landsbanki Securities (UK) Limited to Teathers Limited on 7 October 2008, the name of the Company's
broker and nominated adviser is now Teathers Limited of: 
      
    Beaufort House 
    15 St Botolph Street 
    London EC3A 7QR.

    Enquiries 

 Lipoxen PLC
 M. Scott Maguire, Chief Executive Officer  +44 (0)20 7691 3583 

 Teathers Limited (nominated adviser)
 Shaun Dobson / Claes Spg                   +44 (0)20 7426 9000

 Citigate Dewe Rogerson                     +44 (0)20 7638 9571
 David Dible / Heather Keohane

    Notes to Editors
    Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the development of high value differentiated biologicals, vaccines
and oncology drugs. Products currently under development include improved formulations of important biologicals such as erythropoietin
(EPO), G-CSF, insulin and Interferon-alpha. Lipoxen has two products in clinical development SuliXen, a long acting insulin and long-acting
EPO. These novel products, which are based on Lipoxen's proprietary PolyXen� technology, each address markets in excess of US$1 billion. 

    Lipoxen's technology is designed to improve the stability, biological half-life and immunologic characteristics of therapeutic proteins
naturally. Lipoxen has two further naturally-derived proprietary delivery technologies, ImuXen� and a related liposomal technology for the
formulation of cytotoxic oncology drugs, which are being developed to enhance the efficacy and safety of various vaccines such as a
multivalent Hepatitis B-E and pneumococcal vaccines, as well as a number of anti-cancer agents like paclitaxel. The Company's proprietary
delivery technologies are attracting significant interest and Lipoxen is currently co-developing products with the Serum Institute of India
Limited (one of the world's leading vaccine companies, India's largest biotech company and a major shareholder in Lipoxen) and has license
agreements in place with Baxter International and InterVet, a leading animal health company.

    Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange in January 2006.

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
APPFSWSWASASELS

Lipoxen (LSE:LPX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Lipoxen (LSE:LPX)
Historical Stock Chart
From Jul 2023 to Jul 2024